Home/Filings/4/0000882104-15-000073
4//SEC Filing

PDL BIOPHARMA, INC. 4

Accession 0000882104-15-000073

CIK 0000882104operating

Filed

Oct 4, 8:00 PM ET

Accepted

Oct 5, 6:54 PM ET

Size

4.9 KB

Accession

0000882104-15-000073

Insider Transaction Report

Form 4
Period: 2015-09-29
Stone Christopher Lewis
VP and General Counsel
Transactions
  • Award

    Common stock

    2015-09-29$4.95/sh+15,291$75,690155,764 total
Footnotes (1)
  • [F1]The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved, based upon the following schedule: 50% on December 2016; 16.66% on December 2017; 16.66% on December 2018; and 16.66% on December 2019.

Issuer

PDL BIOPHARMA, INC.

CIK 0000882104

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000882104

Filing Metadata

Form type
4
Filed
Oct 4, 8:00 PM ET
Accepted
Oct 5, 6:54 PM ET
Size
4.9 KB